Vliv sledování hCG na úzkost, depresi a kvalitu života u žen s gestační trofoblastickou chorobou

Download PDF English version

Authors: G. M. Grecco ¹; E. De Sá V. Abuchaim ²; F. P. Dittmer ¹; I. Maestá ³; A. Braga ⁴; E. Araujo Júnior ¹; S. Y. Sun ¹
Authors‘ workplace: Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), São Paulo-SP, Brazil ¹; Department of Women’s Health Nursing, Paulista School of Nursing, Federal University of São Paulo (EPE-UNIFESP), São Paulo-SP, Brazil ²; Department of Tocoginecology, Botucatu Medical School – São Paulo State University (UNESP), Botucatu-SP, Brazil ³; Department of Obstetrics and Gynecology – Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro-RJ, Brazil ⁴
Published in: Ceska Gynekol 2025; 90(4): 299-308
Category: Original Article
doi: https://doi.org/10.48095/cccg2025299

Overview

Cíl: Posoudit vliv normalizace hormonu lidského choriového gonadotropinu na úzkost, symptomy deprese a kvalitu života u pacientek s gestační trofoblastickou chorobou a identifikovat rizikové faktory spojené s těmito výsledky. Metody: Tato longitudinální studie zahrnovala 51 žen, které byly v období postmolárního sledování nebo během léčby gestační trofoblastické neoplazie v letech 2017–2019 ve dvou brazilských centrech pro trofoblastickou chorobu. Výsledky: Normalizace hladiny lidského choriového gonadotropinu vedla k významnému snížení skóre deprese a zvýšení skóre v oblasti fyzického zdraví v obou studijních skupinách, konkrétně ve skupině s hydatiformní molou a gestační trofoblastickou neoplazií. Mít děti a touha po dětech byly spojeny s nižším skóre deprese a úzkosti a vyšším skóre v oblasti psychického zdraví, která se týká kvality života. Vnímání zdraví jako „velmi špatného“ bylo spojeno s vyšším skóre deprese a úzkosti a nižším skóre v oblasti kvality života, pokud jde o fyzické zdraví, psychické zdraví a sociální vztahy. Závěr: Remise onemocnění je spojena se snížením symptomů deprese a lepší kvalitou života v oblasti fyzického zdraví. Zatímco negativní vnímání zdraví bylo spojeno s vyšším skóre úzkosti a deprese a špatnou kvalitou života, mít děti a touha po dětech zlepšily symptomy úzkosti a deprese a kvalitu života v oblasti psychického zdraví.

Klíčová slova:

kvalita života – úzkost – deprese – gestační trofoblastická choroba

Sources

1. Chawla T, Bouchard-Fortier G, Turashvili G et al. Gestational trophoblastic disease: an update. Abdom Radiol (NY) 2023; 48 (5): 1793–1815. doi: 10.1007/s00261-023-03820-5.

2. Feng F, Xiang Y. Surgical management of chemotherapy-resistant gestational trophoblastic neoplasia. Expert Rev Anticancer Ther 2010; 10 (1): 71–80. doi: 10.1586/era.09.169.

3. Ngan HY, Seckl MJ, Berkowitz RS et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet 2021; 155 (Suppl 1): 86–93. doi: 10.1002/ijgo.13877.

4. Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol 2021; 137 (2): 355–370. doi: 10.1097/AOG. 0000000000004240.

5. Joneborg U. Epidemiology of gestational trophoblastic disease. Hematol Oncol Clin North Am 2024; 38 (6): 1173–1190. doi: 10.1016/j.hoc. 2024.07.003.

6. Weng Y, Liu Y, Benjoed C et al. Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia: a 19-year retrospective analysis. J Zhejiang Univ Sci B 2022; 23 (3): 218–229. doi: 10.1631/jzus.B2100895.

7. Zhong L, Song L, Yin R et al. Risk factors for gestational trophoblastic neoplasia development of singleton normal fetus with partial hydatidiform mole pregnancy: a retrospective cohort and literature review. J Obstet Gynaecol Res 2023; 49 (2): 479–486. doi: 10.1111/jog. 15488.

8. Sun SY, Amed AM, Bertini AM et al. Incidence of hydatidiform mole at the Escola Paulista de Medicina. Rev Assoc Med Bras 1992; 38 (4): 217–220.

9. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 2011; 204 (1): 11–18. doi: 10.1016/j.ajog.2010.06.072.

10. Ngan HY, Seckl MJ, Berkowitz RS et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2018; 143 (Suppl 2): 79–85. doi: 10.1002/ijgo.12615.

11. Freitas F, Braga A, Viggiano M et al. Gestational trophoblastic neoplasia lethality among Brazilian women: a retrospective national cohort study. Gynecol Oncol 2020; 158 (2): 452–459. doi: 10.1016/j.ygyno.2020.04.704.

12. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112 (3): 654–662. doi: 10.1016/j.ygyno.2008.08.005.

13. Block LJ, Eysbouts YK, Bastiaans S et al. Evaluation of the psychosocial impact and received care in patients with gestational trophoblastic disease –⁠ a qualitative interview based study. J Psychosom Obstet Gynaecol 2025; 46 (1): 2451992. doi: 10.1080/0167482X.2025.245 1992.

14. Wenzel LB, Berkowitz RS, Robinson S et al. The psychological, social, and sexual consequences of gestational trophoblastic disease. Gynecol Oncol 1992; 46 (1): 74–81. doi: 10.1016/0090-8258 (92) 90200-3.

15. Buza N. Gestational trophoblastic disease: contemporary diagnostic approach. Surg Pathol Clin 2022; 15 (2): 197–218. doi: 10.1016/ j.path.2022.02.002.

16. Horowitz NS, Wenzel LB. Psychosocial consequences of gestational trophoblastic disease. In: Hancock BW, Seckl MJ, Berkowitz RS et al (eds). Gestational trophoblastic disease. 4th ed. London: International Society for the Study of Trophoblastic Disease 2015 : 1–9.

17. Blok LJ, Frijstein MM, Eysbouts YK et al. The psychological impact of gestational trophoblastic disease: a prospective observational multicentre cohort study. BJOG 2022; 129 (3): 444–449. doi: 10.1111/1471-0528.16849.

18. Jewell EL, Aghajanian C, Montovano M et al. Association of ß-hCG surveillance with emotional, reproductive, and sexual health in women treated for gestational trophoblastic neoplasia. J Womens Health (Larchmt) 2018; 27 (3): 387–393. doi: 10.1089/jwh.2016.6208.

19. Quinlivan JA, Ung KA, Petersen RW. The impact of molar pregnancy on the male partner. Psychooncology 2012; 21 (9): 970–976. doi: 10.1002/pon.1992.

20. Lok CA, Donker M, Calff MM et al. Psychologic impact of follow-up after low-risk gestational trophoblastic disease. J Reprod Med 2011; 56 (1–2): 47–52.

21. Flam F, Magnusson C, Lundström-Lindstedt V et al. Psychosocial impact of persistent trophoblastic disease. J Psychosom Obstet Gynaecol 1993; 14 (4): 241–248. doi: 10.3109/01674829309084447.

22. Wenzel LB, Berkowitz RS, Robinson S et al. Psychological, social and sexual effects of gestational trophoblastic disease on patients and their partners. J Reprod Med 1994; 39 (3): 163–167.

23. Wenzel L, Berkowitz RS, Newlands E et al. Quality of life after gestational trophoblastic disease. J Reprod Med 2002; 47 (5): 387–394.

24. Braga A, Uberti EM, Fajardo MC et al. Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO 2000 Consensus. J Reprod Med 2014; 59 (5–6): 241–247.

25. Stafford L, McNally OM, Gibson P et al. Long-term psychological morbidity, sexual functioning, and relationship outcomes in women with gestational trophoblastic disease. Int J Gynecol Cancer 2011; 21 (7): 1256–1263. doi: 10.1097/IGC.0b013e3182259c04.

26. Di Mattei V, Mazzetti M, Perego G et al. Psychological aspects and fertility issues of GTD. Best Pract Res Clin Obstet Gynaecol 2021; 74 : 53–66. doi: 10.1016/j.bpobgyn.2020. 10.007.

27. Governo do Estado de São Paulo. Fundação Sistema Estadual de Análise de Dados. Evolução populacional. 2022 [online]. Available from: https: //populacao.seade.gov.br/evolucao-populacional-esp/.

28. Spielberger CD. State-Trait Anxiety Inventory: Bibliography. 2nd ed. Palo Alto, CA: Consulting Psychologists Press 1989.

29. Spielberger CD, Gorsuch RL, Lushene R et al. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press 1983.

30. Gorenstein C, Andrade L. Inventário de Depressão de Beck: propriedades psicométricas da versão em português. Rev Psiquiatr Clin 1998; 25 : 245–250.

31. Andrade LH, Viana MC, Silveira CM. Epidemiology of women’s psychiatric disorders. Rev Psiquiatr Clin 2006; 33 : 43–54.

32. World Health Organization (WHO). WHOQOL-bref introduction, administration, scoring and generic version of the assessment: field trial version 1996. 2005 [online]. Available from: www.who.int/mental_health?media?en?76.pdf.

33. Di Mattei VE, Carnelli L, Bernardi M et al. An investigative study into psychological and fertility sequelae of gestational trophoblastic disease: the impact on patients’ perceived fertility, anxiety and depression. PLoS One 2015; 10 (6): e0128354. doi: 10.1371/journal.pone.0128354.

34. Ferreira EG, Maestá I, Michelin OC et al. Assessment of quality of life and psychologic aspects in patients with gestational trophoblastic disease. J Reprod Med 2009; 54 (4): 239–244.

36. França AC, Uberti EM, Muller KP et al. Emotional and clinical aspects observed in women with gestational trophoblastic disease: a multidisciplinary action. Rev Bras Ginecol Obstet 2022; 44 (4): 343–351. doi: 10.1055/s-0042-1742681.

37. Ireson J, Jones G, Winter M et al. Systematic review of health-related quality of life and pacient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach. Lancet Oncol 2018; 19 (1): e56–e64. doi: 10.1016/S1470-2045 (17) 30686-1.

38. Uberti EM, Fajardo MC, da Cunha AG et al. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian Women. Rev Bras Ginecol Obstet 2015; 37 (6): 258–265. doi: 10.1590/SO100-720320150005366.